Citric acid
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Citric acid
- Molecular weight
- 192.12
- Structure (SMILES)
- O=C(O)CC(O)(CC(=O)O)C(=O)O
- citric acid component of clenpiq
- Citric acid component of clenpiq
- citric acid component of phexxi
- Citric acid component of phexxi
- citric acid component of prepopik
- Citric acid component of prepopik
- citric acid component of renacidin
- Citric acid component of renacidin
- urologic g
- Urologic g
- 1 2 3 propanetricarboxylic acid 2 hydroxy
- 1,2,3-PROPANETRICARBOXYLIC ACID, 2-HYDROXY-
- acidum citricum
- Acidum citricum
- ACIDUM CITRICUM [WHO-IP LATIN]
- acidum citricum monohydrate
- Acidum citricum monohydrate
- acidum citricum who ip latin
- aciletten
- Aciletten
- anhydrous citric acid
- Anhydrous citric acid
- ANHYDROUS CITRIC ACID [II]
- ANHYDROUS CITRIC ACID [JAN]
- ANHYDROUS CITRIC ACID [MART.]
- ANHYDROUS CITRIC ACID [USP MONOGRAPH]
- anhydrous citric acid 1197 0 mg potassium bicarbonate 967 5 mg sodium citrate anhydrous 835 5 mg
- anhydrous citric acid ii
- anhydrous citric acid jan
- anhydrous citric acid mart
- anhydrous citric acid usp monograph
- b1650
- B1650
- citrate
- Citrate
And 59 more, listed on the interactive page.
- ATC classification codes
- A09AB04
Sources for recorded values
- CAS registry numbers
- 77-92-9
- ChEMBL ID
- CHEMBL1261
- InChIKey
- KRKNYBCHXYNGOX-UHFFFAOYSA-N
- FDA ingredient codes (UNII)
- XF417D3PSL
- 311
- 19782904
- 88113319
- 21183
- 221946
- 1312366
- Applicant
- UNITED GUARDIAN
- Approval date
- 2 Oct 1990
- Application number
- NDA019481
- Patents
- 0
- Designations
- 1
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- citric acid
- Type
- Metabolite
Administration routes
- Oral
- topical
Mechanisms of action
- Action
- Agonist
- Action type
- Agonist
- Target
- TRPP2
- Gene symbol
- PKD2L1
- Protein identifier
- Q9P0L9
- Median affinity
- 1.7
- Affinity units
- pEC50
- Condition
- Kidney Calculi
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004253
- Subject identifier
- D007669
- Condition
- Renal Insufficiency
- Highest recorded phase
- 3
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition
- Nephrocalcinosis
- Highest recorded phase
- 3
- Condition identifier
- HP:0000121
- Subject identifier
- D009397
- Condition
- Tension-Type Headache
- Highest recorded phase
- 2
- Condition identifier
- HP:0012228
- Subject identifier
- D018781
- Condition
- Cataract
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0005129
- Subject identifier
- D002386
- Condition
- Osteoarthritis
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0005178
- Subject identifier
- D010003
- Condition identifier
- EFO_0000384
- Condition identifier
- EFO_0006859
- Condition identifier
- EFO_0009518
- Condition identifier
- EFO_0009909
- Highest recorded phase
- 2
- Condition identifier
- HP_0000083
- Condition identifier
- HP_0002901
- Condition identifier
- HP_0012228
- Condition identifier
- MONDO_0001106
- Condition identifier
- MONDO_0001567
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0002492
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005011
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005178
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005372
- Condition identifier
- MONDO_0005647
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0024647
- Condition identifier
- MONDO_0100192
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0850098
- Event
- analgesic asthma syndrome
- Reports
- 1
- Reporting signal score
- 5.93494
- Event
- anorectal discomfort
- Reports
- 2
- Reporting signal score
- 7.0949
- Event
- b precursor type acute leukaemia
- Reports
- 2
- Reporting signal score
- 11.4885
- Event
- blood calcium decreased
- Reports
- 3
- Reporting signal score
- 7.38152
- Event
- colitis
- Reports
- 6
- Reporting signal score
- 12.3586
- Event
- dermatitis
- Reports
- 3
- Reporting signal score
- 6.66792
- Event
- device temperature issue
- Reports
- 1
- Reporting signal score
- 7.83919
- Event
- drug hypersensitivity
- Reports
- 13
- Reporting signal score
- 13.5491
- Event
- graft versus host disease in skin
- Reports
- 2
- Reporting signal score
- 7.03147
- Event
- haemorrhage
- Reports
- 7
- Reporting signal score
- 10.377
- Event
- hyponatraemic coma
- Reports
- 1
- Reporting signal score
- 6.74087
- Event
- imaging procedure artifact
- Reports
- 3
- Reporting signal score
- 28.0541
- Event
- intestinal congestion
- Reports
- 1
- Reporting signal score
- 6.11171
- Event
- medical device site fibrosis
- Reports
- 1
- Reporting signal score
- 6.17835
- Event
- mucosal dryness
- Reports
- 2
- Reporting signal score
- 7.61942
- Event
- nasogastric output high
- Reports
- 1
- Reporting signal score
- 7.23318
- Event
- ochronosis
- Reports
- 1
- Reporting signal score
- 6.21341
- Event
- oropharyngeal discolouration
- Reports
- 1
- Reporting signal score
- 7.4338
- Event
- product barcode issue
- Reports
- 4
- Reporting signal score
- 25.1062
- Event
- product label issue
- Reports
- 2
- Reporting signal score
- 7.33843
- Event
- radiation alopecia
- Reports
- 2
- Reporting signal score
- 17.4374
- Event
- swollen tongue
- Reports
- 4
- Reporting signal score
- 7.08767
- Event
- tongue discomfort
- Reports
- 2
- Reporting signal score
- 7.64279
- Event
- toxic epidermal necrolysis
- Reports
- 9
- Reporting signal score
- 29.7269
- Event
- upper airway obstruction
- Reports
- 2
- Reporting signal score
- 8.87596
- NCT00249951
- NCT01012349
- NCT01421160
- NCT01602068
- NCT01754779
- NCT01962116
- Dose
- 1 bottle
- Route
- Oral
- How often
- Split-dose regimen
- Do not drink alcohol
- Do not drink anything colored red or purple
- Do not eat solid food or dairy on the day before colonoscopy
- No solid food or dairy
- Stop liquids at least 2 hours before colonoscopy
- Take with clear liquids
- Hydrogen bond acceptors
- 4
- Hydrogen bond donors
- 4
- Polar surface area
- 132.13
- Calculated partition coefficient (ALogP)
- -1.25
- Calculated partition coefficient (XLogP)
- -1.7
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 5
- Heavy atoms
- 13
- Molecular formula
- C6H8O7
- Monoisotopic mass
- 192.02700259
- Natural product
- Yes
- 0121-0595
- 0121-1190
- 0327-0012
- 0942-0641
- 0942-6305
- 0942-6307
- 0942-6308
- 0942-6312
- 0942-6316
- 0942-6320
- 0942-6322
- 0942-6326
- 0942-9001
- 0942-9201
- 0942-9202
- 0942-9393
- 0942-9394
- 0942-9398
- 50268-182
- 50268-183
- 53877-108
- 53877-109
- 53877-110
- 60687-832
- 60687-834
And 9 more, listed on the interactive page.
- Recorded assays
- 2,354
- Active assays
- 41
- Confirmatory
- Other
- Screening
- Anticoagulants
- Calcium Chelating Agents
Related records
Trials (58)
- 68Ga Citrate PET/MRI for Evaluation of Fever of Unknown Origin (FUO)
- 68Ga-citrate PET/MR Imaging for Glioma
- A Bioequivalence Study of Citrate Free Mirikizumab (LY3074828) in Healthy Participants
- A Cross-sectional Study to Measure Cough in Severe Asthma
- A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke
- A Pilot Study of Commercially Available Bowel Preparation Regimens Packaged and Ingested Via Vegan Capsules
- A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy
- A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy
- A Study of the Efficacy and Safety of Bowklean and Klean-Prep With Dulcolax for the Bowel Preparation Prior Colonoscopy
- A Study of Two Formulations (Both Refrigerated and Room Temperature) Using an Autoinjector Device in Healthy Participants
- Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants
- Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia
- Arterial pH and Total Body Nitrogen Balances in APD
- Biological and Clinical Measurements Following Systemic Leakage When a Citrate or Heparin Lock is Used
- Bismuth Based Quadruple Therapy 10 Days in Children
- Bone in CKD Alkali Response (BICARb Pilot Trial)
- Bowel Preparation in Elective Pediatric Colorectal Surgery
- Citrate 4% Versus Heparinised Saline in Preventing Peripherally Inserted Central Catheter (PICC) Occlusions
- Citrate Anticoagulation in Renal Replacement Therapy: Impact of a High Post-filter Calcium Target on Efficacy
- Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances
In development for (6)
- Acute kidney injury Phase 3
- Cataract Phase 2
- Kidney failure Phase 3
- Nephrocalcinosis Phase 3
- Nephrolithiasis Phase 2
- Osteoarthritis Phase 1
Other linked conditions (3)
- Crohn disease
- Head and neck cancer
- Urolithiasis